Dear Ms. Drake:

Please refer to your supplemental new drug application dated June 27, 2008 received June 30, 2008, submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act for CUBICIN® (daptomycin for injection).

We acknowledge receipt of your submission dated September 17, 2008, and your electronic mail correspondence dated February 6, 2009.

This “Changes Being Effected in 30 days” supplemental new drug application provides for revisions to the “Preparation of CUBICIN® for Administration” section of the package insert. Specifically, a new paragraph has been added advising that CUBICIN® should not be used in conjunction with ReadyMED® elastomeric infusion pumps.

We completed our review of this application as amended, and it is approved effective on the date of this letter, for use as recommended in the agreed-upon labeling text, and with the minor editorial revisions listed below:

- Your originally proposed language to be added to the “Preparation of CUBICIN® for Administration” section:

  "CUBICIN should not be used in conjunction with ReadyMED® elastomeric infusion pumps (Cardinal Health, Inc.). Stability studies of CUBICIN solutions stored in ReadyMED® elastomeric infusion pumps identified an impurity (2-mercaptobenzothiazole) leaching from this pump system into the CUBICIN solution."
As soon as possible, but no later than 14 days from the date of this letter, please submit the content of labeling [21 CFR 314.50(1)] in structured product labeling (SPL) format as described at http://www.fda.gov/oc/datacouncil/spl.html that is identical to the label submitted June 27, 2008 (with the exception of the above listed minor editorial revisions). Upon receipt, we will transmit that version to the National Library of Medicine for public dissemination. For administrative purposes, designate this submission "SPL for approved supplement NDA 21-572/S-021.”

If you issue a letter communicating important information about this drug product (i.e., a “Dear Health Care Professional” letter), we request that you submit a copy of the letter to this NDA and a copy to the following address:

MEDWATCH
Food and Drug Administration
Suite 12B05
5600 Fishers Lane
Rockville, MD 20857

We remind you that you must comply with reporting requirements for an approved NDA (21 CFR 314.80 and 314.81).

If you have any questions, call J. Christopher Davi, MS, Senior Regulatory Project Manager, at (301) 796-0702.

Sincerely,

{See appended electronic signature page}

Sumathi Nambiar, MD, MPH
Deputy Director for Safety
Division of Anti-Infective and Ophthalmology Products
Office of Antimicrobial Products
Center for Drug Evaluation and Research
This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.

/s/

Sumathi Nambiar
2/10/2009 03:52:47 PM